Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06270407

The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery

The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery - A Multicenter Randomized Controlled Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
3,000 (estimated)
Sponsor
St. Olavs Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Study objective: This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or seroma, or if it may increase the risk of blood clots. Eligible patients: Patients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery. Study intervention: Participants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules.

Detailed description

Any serious postoperative complication needing intervention, specifically re-bleeding, wound infection, wound rupture, or the occurrence of blood clots for the first 30 days after surgery will be registered through the following interventions: * Screening of patient medical records * Distribution of an electronic self-report form (eForsk®) to participating patients at postoperative day 30 * Follow-up phone call to verify data after day 30. The study is terminated after the final phone call. All study data will be registered in an electronic, pseudonymous web-based registration form (eCRF/Viedoc®). Number of participants: To assess the effect of TXA on the defined surgical complications compared to placebo, 1500 patients are needed in each group. Data monitoring committee: A data monitoring committee consisting of a group of independent scientists will be appointed for this study to monitor the safety and scientific integrity of this human research intervention.

Conditions

Interventions

TypeNameDescription
DRUGTranexamic Acid 100 MG/MLIf surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
DRUG0.9%sodium chlorideIf surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.

Timeline

Start date
2024-10-01
Primary completion
2028-12-31
Completion
2029-12-31
First posted
2024-02-21
Last updated
2024-12-04

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT06270407. Inclusion in this directory is not an endorsement.